Indirubin-3′-oxime (Synonyms: IDR3O; I3O)

Name: Indirubin-3′-oxime
Brand: MedChemExpress
SKU: HY-139254
Rating: 4.5 (0 reviews)

製品番号: HY-139254 純度: 99.10%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

Indirubin-3′-oxime (IDR3O), a synthetic derivative of indirubin, is a potent inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3β (GSK3β). Indirubin-3′-oxime directly inhibits the activity of all three isoforms of JNK (JNK1, JNK2, and JNK3), with IC₅₀s of 0.8 μM, 1.4 μM, and 1.0 μM, respectively. Indirubin-3′-oxime can enhance height growth via activation of Wnt/β-catenin signaling in chondrocytes.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

Indirubin-3′-oxime 構造式

CAS 番号 : 667463-82-3

容量	価格（税別）	在庫状況	数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 121	在庫あり	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 121	在庫あり	Estimated Time of Arrival: December 31
Solid
5 mg	$110	在庫あり	Estimated Time of Arrival: December 31
10 mg	$160	在庫あり	Estimated Time of Arrival: December 31
25 mg	$320	在庫あり	Estimated Time of Arrival: December 31
50 mg	$490	在庫あり	Estimated Time of Arrival: December 31
100 mg	$730	在庫あり	Estimated Time of Arrival: December 31
200 mg		お問い合わせ
500 mg		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 0 publication(s) in Google Scholar

CDK アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

CDK1 CDK2 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK9 CDK11 CDK12 CDK13 CDK14 CDK16 CDK19 CDC CLK Pho85 CDK10 CDK15 CDK17 CDK18 CDK20 PITSLRE

GSK-3 アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

GSK-3 GSK-3α GSK-3β

JNK アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

JNK1 JNK2 JNK3 JNK

Wnt アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

Wnt1 Wnt3 Wnt5 Wnt7 Wnt11

生物活性
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

IC₅₀ & Target^[1]^[2]^[3]

JNK1

0.8 μM (IC₅₀)

JNK2

1.4 μM (IC₅₀)

JNK3

1 μM (IC₅₀)

GSK-3β

CDK

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	27 3 Compound: 5a	Antiproliferative activity against apoptosis resistant human A549 cells after 72 hrs by MTT assay Antiproliferative activity against apoptosis resistant human A549 cells after 72 hrs by MTT assay	[PMID: 26883150]
A549	IC₅₀	5.82 3 Compound: IM	Growth inhibition of human A549 cells incubated for 3 days by SRB assay Growth inhibition of human A549 cells incubated for 3 days by SRB assay	[PMID: 28625363]
B16-F10	IC₅₀	5.4 3 Compound: 5a	Antiproliferative activity against apoptosis sensitive mouse B16F10 cells after 72 hrs by MTT assay Antiproliferative activity against apoptosis sensitive mouse B16F10 cells after 72 hrs by MTT assay	[PMID: 26883150]
A549	IC₅₀	27 3 Compound: 5a	Antiproliferative activity against apoptosis resistant human A549 cells after 72 hrs by MTT assay Antiproliferative activity against apoptosis resistant human A549 cells after 72 hrs by MTT assay	[PMID: 26883150]
A549	IC₅₀	4.04 3 Compound: IO	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 38295524]
HepG2	IC₅₀	15 3 Compound: 2	Antiproliferative activity against human HepG2 cells assessed cell survival after 24 hrs by alamarBlue assay Antiproliferative activity against human HepG2 cells assessed cell survival after 24 hrs by alamarBlue assay	[PMID: 25765906]
HL-60	GI₅₀	36.6 3 Compound: 18	Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition measured after 3 days by trypan blue staining based inverted microscope method Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition measured after 3 days by trypan blue staining based inverted microscope method	[PMID: 34161865]
A549	IC₅₀	4.17 3 Compound: IDM	Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of Niraparib by CCK8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of Niraparib by CCK8 assay	[PMID: 37832229]
Hs 683	IC₅₀	6 3 Compound: 5a	Antiproliferative activity against apoptosis sensitive human Hs683 cells after 72 hrs by MTT assay Antiproliferative activity against apoptosis sensitive human Hs683 cells after 72 hrs by MTT assay	[PMID: 26883150]
A549	IC₅₀	5.82 3 Compound: IM	Growth inhibition of human A549 cells incubated for 3 days by SRB assay Growth inhibition of human A549 cells incubated for 3 days by SRB assay	[PMID: 28625363]
A549	IC₅₀	6.06 3 Compound: IDM	Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of olaparib by CCK8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of olaparib by CCK8 assay	[PMID: 37832229]
HuCCT-1	IC₅₀	5 3 Compound: 18	Antiproliferative activity against human HuCCT-1 cells assessed as cell growth inhibition measured upto 72 hrs by CCK-8 assay Antiproliferative activity against human HuCCT-1 cells assessed as cell growth inhibition measured upto 72 hrs by CCK-8 assay	[PMID: 34161865]
A549	IC₅₀	8.21 3 Compound: IDM	Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay	[PMID: 37832229]
HUVEC	IC₅₀	0.36 3 Compound: 18	Antiproliferative activity against HUVEC cells assessed as cell growth inhibition measured after 3 days by [3H]-thymidine incorporation assay Antiproliferative activity against HUVEC cells assessed as cell growth inhibition measured after 3 days by [3H]-thymidine incorporation assay	[PMID: 34161865]
MV4-11	IC₅₀	30 1 Compound: 18	Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition measured after 72 hrs by tetrazolium staining based WST-8 assay Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition measured after 72 hrs by tetrazolium staining based WST-8 assay	[PMID: 34161865]
B16-F10	IC₅₀	5.4 3 Compound: 5a	Antiproliferative activity against apoptosis sensitive mouse B16F10 cells after 72 hrs by MTT assay Antiproliferative activity against apoptosis sensitive mouse B16F10 cells after 72 hrs by MTT assay	[PMID: 26883150]
KB	IC₅₀	5.34 3 Compound: IM	Growth inhibition of human KB cells incubated for 3 days by SRB assay Growth inhibition of human KB cells incubated for 3 days by SRB assay	[PMID: 28625363]
LoVo	IC₅₀	8.9 3 Compound: 5a	Antiproliferative activity against human LoVo cells after 72 hrs by MTT assay Antiproliferative activity against human LoVo cells after 72 hrs by MTT assay	[PMID: 26883150]
HCT-116	IC₅₀	0.83 3 Compound: IDM	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of Niraparib by CCK8 assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of Niraparib by CCK8 assay	[PMID: 37832229]
LXFL 529	IC₅₀	3 3 Compound: 18	Cytotoxicity against human LXFL 529 cells assessed as cell growth inhibition measured after 3 days by SRB assay Cytotoxicity against human LXFL 529 cells assessed as cell growth inhibition measured after 3 days by SRB assay	[PMID: 34161865]
HCT-116	IC₅₀	1.37 3 Compound: IDM	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of olaparib by CCK8 assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of olaparib by CCK8 assay	[PMID: 37832229]
HCT-116	IC₅₀	3.88 3 Compound: IDM	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay	[PMID: 37832229]
MCF7	IC₅₀	9.2 3 Compound: 5a	Antiproliferative activity against apoptosis sensitive human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against apoptosis sensitive human MCF7 cells after 72 hrs by MTT assay	[PMID: 26883150]
MCF7	IC₅₀	3.3 3 Compound: 18	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 3 days by SRB assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 3 days by SRB assay	[PMID: 34161865]
HCT-116	IC₅₀	4.22 3 Compound: IO	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 38295524]
MCF7	IC₅₀	6.81 3 Compound: IM	Growth inhibition of human MCF7 cells incubated for 3 days by SRB assay Growth inhibition of human MCF7 cells incubated for 3 days by SRB assay	[PMID: 28625363]
MDA-MB-231	IC₅₀	7.59 3 Compound: IM	Growth inhibition of human MDA-MB-231 cells incubated for 3 days by SRB assay Growth inhibition of human MDA-MB-231 cells incubated for 3 days by SRB assay	[PMID: 28625363]
HL-60	GI₅₀	36.6 3 Compound: 18	Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition measured after 3 days by trypan blue staining based inverted microscope method Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition measured after 3 days by trypan blue staining based inverted microscope method	[PMID: 34161865]
NCI-H23	IC₅₀	11.25 3 Compound: Indirubin-3'-oxime	Cytotoxicity against human NCI-H23 cells by colorimetric method Cytotoxicity against human NCI-H23 cells by colorimetric method	[PMID: 32916298]
HUVEC	IC₅₀	0.36 3 Compound: 18	Antiproliferative activity against HUVEC cells assessed as cell growth inhibition measured after 3 days by [3H]-thymidine incorporation assay Antiproliferative activity against HUVEC cells assessed as cell growth inhibition measured after 3 days by [3H]-thymidine incorporation assay	[PMID: 34161865]
Oocyte	IC₅₀	0.18 3 Compound: 18	Inhibition of starfish oocyte CDK1/Cyclin B using histone H1 as substrate incubated for 10 mins in presence of [gamma-32P]ATP by scintillation counter analysis Inhibition of starfish oocyte CDK1/Cyclin B using histone H1 as substrate incubated for 10 mins in presence of [gamma-32P]ATP by scintillation counter analysis	[PMID: 34161865]
PC-3	IC₅₀	24.3 3 Compound: 5a	Antiproliferative activity against apoptosis sensitive human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against apoptosis sensitive human PC3 cells after 72 hrs by MTT assay	[PMID: 26883150]
HepG2	IC₅₀	15 3 Compound: 2	Antiproliferative activity against human HepG2 cells assessed cell survival after 24 hrs by alamarBlue assay Antiproliferative activity against human HepG2 cells assessed cell survival after 24 hrs by alamarBlue assay	[PMID: 25765906]
HepG2	IC₅₀	5.66 3 Compound: IO	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 38295524]
PC-3	IC₅₀	15.8 3 Compound: Indirubin-3'-oxime	Cytotoxicity against human PC3 cells by colorimetric method Cytotoxicity against human PC3 cells by colorimetric method	[PMID: 32916298]
SK-MEL-28	IC₅₀	26.6 3 Compound: 5a	Antiproliferative activity against apoptosis resistant human SK-MEL-28 cells after 72 hrs by MTT assay Antiproliferative activity against apoptosis resistant human SK-MEL-28 cells after 72 hrs by MTT assay	[PMID: 26883150]
Hs 683	IC₅₀	6 3 Compound: 5a	Antiproliferative activity against apoptosis sensitive human Hs683 cells after 72 hrs by MTT assay Antiproliferative activity against apoptosis sensitive human Hs683 cells after 72 hrs by MTT assay	[PMID: 26883150]
SW-620	IC₅₀	13.5 3 Compound: Indirubin-3'-oxime	Cytotoxicity against human SW620 cells by colorimetric method Cytotoxicity against human SW620 cells by colorimetric method	[PMID: 32916298]
HuCCT-1	IC₅₀	5 3 Compound: 18	Antiproliferative activity against human HuCCT-1 cells assessed as cell growth inhibition measured upto 72 hrs by CCK-8 assay Antiproliferative activity against human HuCCT-1 cells assessed as cell growth inhibition measured upto 72 hrs by CCK-8 assay	[PMID: 34161865]
U-373MG ATCC	IC₅₀	18 3 Compound: 5a	Antiproliferative activity against apoptosis resistant human U373 cells after 72 hrs by MTT assay Antiproliferative activity against apoptosis resistant human U373 cells after 72 hrs by MTT assay	[PMID: 26883150]
KB	IC₅₀	5.34 3 Compound: IM	Growth inhibition of human KB cells incubated for 3 days by SRB assay Growth inhibition of human KB cells incubated for 3 days by SRB assay	[PMID: 28625363]
LXFL 529	IC₅₀	3 3 Compound: 18	Cytotoxicity against human LXFL 529 cells assessed as cell growth inhibition measured after 3 days by SRB assay Cytotoxicity against human LXFL 529 cells assessed as cell growth inhibition measured after 3 days by SRB assay	[PMID: 34161865]
LoVo	IC₅₀	8.9 3 Compound: 5a	Antiproliferative activity against human LoVo cells after 72 hrs by MTT assay Antiproliferative activity against human LoVo cells after 72 hrs by MTT assay	[PMID: 26883150]
MCF7	IC₅₀	1.41 3 Compound: IDM	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of Niraparib by CCK8 assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of Niraparib by CCK8 assay	[PMID: 37832229]
MCF7	IC₅₀	2.33 3 Compound: IDM	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of olaparib by CCK8 assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of olaparib by CCK8 assay	[PMID: 37832229]
MCF7	IC₅₀	3.3 3 Compound: 18	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 3 days by SRB assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 3 days by SRB assay	[PMID: 34161865]
MCF7	IC₅₀	4.1 3 Compound: IDM	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay	[PMID: 37832229]
MCF7	IC₅₀	6.81 3 Compound: IM	Growth inhibition of human MCF7 cells incubated for 3 days by SRB assay Growth inhibition of human MCF7 cells incubated for 3 days by SRB assay	[PMID: 28625363]
MCF7	IC₅₀	9.2 3 Compound: 5a	Antiproliferative activity against apoptosis sensitive human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against apoptosis sensitive human MCF7 cells after 72 hrs by MTT assay	[PMID: 26883150]
MDA-MB-231	IC₅₀	5.16 3 Compound: IO	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 38295524]
MDA-MB-231	IC₅₀	7.59 3 Compound: IM	Growth inhibition of human MDA-MB-231 cells incubated for 3 days by SRB assay Growth inhibition of human MDA-MB-231 cells incubated for 3 days by SRB assay	[PMID: 28625363]
MV4-11	IC₅₀	1.69 3 Compound: IDM	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of Niraparib by CCK8 assay Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of Niraparib by CCK8 assay	[PMID: 37832229]
MV4-11	IC₅₀	2.36 3 Compound: IDM	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of olaparib by CCK8 assay Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of olaparib by CCK8 assay	[PMID: 37832229]
MV4-11	IC₅₀	30 1 Compound: 18	Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition measured after 72 hrs by tetrazolium staining based WST-8 assay Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition measured after 72 hrs by tetrazolium staining based WST-8 assay	[PMID: 34161865]
MV4-11	IC₅₀	6.01 3 Compound: IDM	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay	[PMID: 37832229]
NCI-H23	IC₅₀	11.25 3 Compound: Indirubin-3'-oxime	Cytotoxicity against human NCI-H23 cells by colorimetric method Cytotoxicity against human NCI-H23 cells by colorimetric method	[PMID: 32916298]
NCM460	IC₅₀	13.13 3 Compound: IDM	Antiproliferative activity against human NCM460 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human NCM460 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK8 assay	[PMID: 37832229]
NCM460	IC₅₀	20.18 3 Compound: IDM	Antiproliferative activity against human NCM460 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of olaparib by CCK8 assay Antiproliferative activity against human NCM460 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of olaparib by CCK8 assay	[PMID: 37832229]
NCM460	IC₅₀	21.13 3 Compound: IDM	Antiproliferative activity against human NCM460 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of Niraparib by CCK8 assay Antiproliferative activity against human NCM460 cells assessed as inhibition of cell viability incubated for 72 hrs in presence of Niraparib by CCK8 assay	[PMID: 37832229]
Oocyte	IC₅₀	0.18 3 Compound: 18	Inhibition of starfish oocyte CDK1/Cyclin B using histone H1 as substrate incubated for 10 mins in presence of [gamma-32P]ATP by scintillation counter analysis Inhibition of starfish oocyte CDK1/Cyclin B using histone H1 as substrate incubated for 10 mins in presence of [gamma-32P]ATP by scintillation counter analysis	[PMID: 34161865]
PC-3	IC₅₀	15.8 3 Compound: Indirubin-3'-oxime	Cytotoxicity against human PC3 cells by colorimetric method Cytotoxicity against human PC3 cells by colorimetric method	[PMID: 32916298]
PC-3	IC₅₀	24.3 3 Compound: 5a	Antiproliferative activity against apoptosis sensitive human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against apoptosis sensitive human PC3 cells after 72 hrs by MTT assay	[PMID: 26883150]
SK-MEL-28	IC₅₀	26.6 3 Compound: 5a	Antiproliferative activity against apoptosis resistant human SK-MEL-28 cells after 72 hrs by MTT assay Antiproliferative activity against apoptosis resistant human SK-MEL-28 cells after 72 hrs by MTT assay	[PMID: 26883150]
SW-620	IC₅₀	13.5 3 Compound: Indirubin-3'-oxime	Cytotoxicity against human SW620 cells by colorimetric method Cytotoxicity against human SW620 cells by colorimetric method	[PMID: 32916298]
U-373MG ATCC	IC₅₀	18 3 Compound: 5a	Antiproliferative activity against apoptosis resistant human U373 cells after 72 hrs by MTT assay Antiproliferative activity against apoptosis resistant human U373 cells after 72 hrs by MTT assay	[PMID: 26883150]

体外実験

In cerebellar granule neurons (CGNs), Indirubin-3′-oxime blocks c-Jun phosphorylation induced by potassium withdrawal and prevented CGNs from apoptosis in a dose dependent manner^[1].
Indirubin-3′-oxime (IDR3O) (PC12 cells; 10 μM) significantly prevent 6OHDA-induced decrease of nuclear localized MEF2D expression^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Indirubin-3′-oxime (0.05 or 0.5 mg/kg; i.p.; daily for 2 or 10 weeks) enhances tibial longitudinal growth in mice without adverse changes in bone thickness parameters^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Three-week-old C57BL/6 mice^[3]
Dosage:	0.05 or 0.5 mg/kg
Administration:	I.p.; daily for 2 or 10 weeks
Result:	The tibial length of mice increased in a dose-dependent manner.

分子量

277.28

分子式

C₁₆H₁₁N₃O₂

CAS 番号

667463-82-3

Appearance

Solid

Color

Brown to red

SMILES

O/N=C1C2=C(C=CC=C2)NC\1=C3C4=C(C=CC=C4)NC\3=O

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (360.65 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.6065 mL	18.0323 mL	36.0646 mL
5 mM	0.7213 mL	3.6065 mL	7.2129 mL
10 mM	0.3606 mL	1.8032 mL	3.6065 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.02 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

純度とドキュメンテーション

純度: 99.10%

Select Batch:

データシート (282 KB) SDS (604 KB)

COA (259 KB) LCMS (98 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Xie Y, et al. Indirubin-3'-oxime inhibits c-Jun NH2-terminal kinase: anti-apoptotic effect in cerebellar granule neurons. Neurosci Lett. 2004;367(3):355-359. [Content Brief]

[2]. Hu S, et al. Indirubin-3-Oxime Effectively Prevents 6OHDA-Induced Neurotoxicity in PC12 Cells via Activating MEF2D Through the Inhibition of GSK3β. J Mol Neurosci. 2015;57(4):561-570. [Content Brief]

[3]. Choi S, et al. Indirubin-3'-oxime stimulates chondrocyte maturation and longitudinal bone growth via activation of the Wnt/β-catenin pathway. Exp Mol Med. 2019;51(9):1-10. Published 2019 Sep 12. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.6065 mL	18.0323 mL	36.0646 mL	90.1616 mL
	5 mM	0.7213 mL	3.6065 mL	7.2129 mL	18.0323 mL
	10 mM	0.3606 mL	1.8032 mL	3.6065 mL	9.0162 mL
	15 mM	0.2404 mL	1.2022 mL	2.4043 mL	6.0108 mL
	20 mM	0.1803 mL	0.9016 mL	1.8032 mL	4.5081 mL
	25 mM	0.1443 mL	0.7213 mL	1.4426 mL	3.6065 mL
	30 mM	0.1202 mL	0.6011 mL	1.2022 mL	3.0054 mL
	40 mM	0.0902 mL	0.4508 mL	0.9016 mL	2.2540 mL
	50 mM	0.0721 mL	0.3606 mL	0.7213 mL	1.8032 mL
	60 mM	0.0601 mL	0.3005 mL	0.6011 mL	1.5027 mL
	80 mM	0.0451 mL	0.2254 mL	0.4508 mL	1.1270 mL
	100 mM	0.0361 mL	0.1803 mL	0.3606 mL	0.9016 mL

Indirubin-3′-oxime Related Classifications

Neurological Disease

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
製品名			カスタマ需要量 *
お名前 *			タイトル
メールアドレス *			電話番号 *
デパートメント			組纖名 *
市区町村			都道府県
国或いは地域 *
必ず会社名を記載ください。個人への返信は行いません。
備考

製品名			Lot #
お名前 *			メールアドレス *
電話番号 *			部門 *
組纖名 *			国或いは地域 *
備考

Indirubin-3′-oxime (Synonyms: IDR3O; I3O)

カスタマーレビュー

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

CDK アイソフォーム固有の製品をすべて表示:

GSK-3 アイソフォーム固有の製品をすべて表示:

JNK アイソフォーム固有の製品をすべて表示:

Wnt アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Indirubin-3′-oxime Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

お名前
メール *

	Sorry, but the email address you supplied was invalid.

Indirubin-3′-oxime (Synonyms: IDR3O; I3O)

カスタマーレビュー

Indirubin-3′-oxime 関連抗体

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

CDK アイソフォーム固有の製品をすべて表示:

GSK-3 アイソフォーム固有の製品をすべて表示:

JNK アイソフォーム固有の製品をすべて表示:

Wnt アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

Indirubin-3′-oxime 関連抗体

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Indirubin-3′-oxime Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

カスタマーレビュー

Request for HNMR Report

Request for HNMR Report